A multicenter randomized open-label trial comparing the efficacy and safety of Infliximab versus Cyclophosphamide in Subjects with Idiopathic Refractory Scleritis CIRIS: Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis
- Conditions
- anterior idiopathic scleritis or anterior and posterior idiopathic scleritisMedDRA version: 20.0Level: PTClassification code 10039705Term: ScleritisSystem Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]
- Registration Number
- EUCTR2017-004969-27-FR
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 53
Adult patients meeting the following criteria may be included in the study.
1.Written informed consent must be provided prior to the performance of any study specific procedures.
2.Male or female, age = 18 at Screening.
3.Weight 40 – 120 kg (88.2 – 264 lbs) at Screening.
4.Diagnosis of anterior idiopathic scleritis or anterior and posterior idiopathic scleritis at least one eye. Scleritis is classified anatomically as anterior based on the principal location of the inflammation. Clinically, anterior scleritis can be divided into diffuse, nodular or necrotizing types.
5.Active disease: defined as (at least) a 2 in sclera inflammation, according to the grading system defined by Sen for sclera inflammation (gradings from 0 to 4).
6.Refractory disease: At screening, subjects must be receiving oral corticosteroids (>10 mg/day prednisone equivalent and <80 mg/day) and at least one other immunosuppressive (azathioprine, methotrexate, mycophenolate mofetyl, cyclosporine, leflunomide); or be intolerant to such immunosuppressive therapies.
7.Topical corticosteroids and/or NSAIDs are permitted provided the dose regimen has been stable for 2 weeks prior to Screening and remain stable throughout the study. Topical treatment for cycloplegia is permitted.
8.Chest X-ray results (postero-anterior and lateral) within 12 weeks prior to screening, with no evidence of active tuberculosis, active infection or malignancy.
9.For female subjects of child-bearing age, a negative serum pregnancy test.
10.For subjects with reproductive potential, a willingness to use adequate contraceptive measures to prevent the subject or the subject’s partner from becoming pregnant during the study. For women in period of childbearing adequate contraceptive measures include hormonal methods used for two or more cycles prior to Screening and 6 months after the last dose treatment should be used (e.g., oral contraceptive pills, contraceptive patch, or contraceptive vaginal ring), barrier methods (e.g., contraceptive sponge, diaphragm used in conjunction with contraceptive foam or jelly, or condom used in conjunction with contraceptive foam or jelly), intrauterine devices (IUD), sterilization (e.g., tubal ligation or a monogamous relationship with a vasectomized partner), and abstinence. For men who are sexually active with a women in period of childbearing adequate contraceptive measures from screening to 6 months after the last dose treatment should be used (For men: barrier methods (condom used in conjunction with contraceptive foam or jelly), sterilization (vasectomy) and abstinence. For his partner: hormonal methods (e.g., oral contraceptive pills, contraceptive patch, or contraceptive vaginal ring), barrier methods (e.g., contraceptive sponge, diaphragm used in conjunction with contraceptive foam or jelly), intrauterine devices (IUD), sterilization (e.g., tubal ligation)).
11.A negative QuantiFERON®-Tuberculosis (TB) test result or, in the event that their QuantiFERON®-TB test result at Screening is positive, all subjects must agree to complete an INH treatment course of at least 6 months.
12.Affiliated to the French social security system.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 23
Subjects will be excluded from the study if they meet any of the following criteria:
1.medical contraindication to administer experimental drugs: Cyclophosphamide (urinary obstruction, bladder inflammation…) or Infliximab (moderate or severe heart failure, classe III /IV classification NYHA…)/low dose Methotrexate (chronic respiratory insufficiency…); and non-experimental drugs (10 % phenylephrine instillation, prednisone, paracetamol, polaramine, folic acid and uromitexan)
2.Infectious scleritis, posterior idiopathic scleritis or scleritis related to systemic diseases (i.e. granulomatosis with polyangiitis, rheumatoid arthritis, lupus, relapsing chondritis, etc.)
3.Active tuberculosis or history of untreated tuberculosis
4.Known positive syphilis serology, HIV antibody, hepatitis B surface antigen or anti-nucleocapsid antibody of hepatitis B virus, and/or hepatitis C antibody.
5.History of malignancy within 5 years prior to Screening other than carcinoma in situ of the cervix or adequately treated, non-metastatic squamous or basal cell carcinoma of the skin.
6.History of severe allergic or anaphylactic reactions to monoclonal antibodies. Hypersensitivity known to cyclophosphamide, to infliximab, to other murine proteins, to methotrexate or to any of the excipients.
7.Infectious disease:
a.Fever or infection requiring treatment with antibiotics within 3 weeks prior to Screening or between Screening and Day 0.
b.History of recurrent infection or predisposition to infection.
8.Known immunodeficiency
9.History of multiple sclerosis and/or demyelinating disorder
10.Laboratory values assessed during Screening:
a.Hemoglobin <8.5 g/dL
b.WBC <3.0 x 103/mm3
c.Platelet count <100 x 103/mm3
d.Glomerular filtration rates (GFR) <30 ml/min.
e.AST/ALT >1.5 x upper limit of normal (ULN)
f. Absolute Neutrophil Count <2.0 x 103/mm3
g. Absolute Lymphocyte Count <0.5 x 103/mm3
11.Use of the following systemic treatments during the specified periods:
a.Any other previous systemic biological therapy, including anti-TNF
b.Treatment with any systemic alkylating agents within 12 months prior to Screening or between Screening and Day 0 (e.g., cyclophosphamide, chlorambucil)
c.Any live (attenuated) vaccine within 3 months prior to Screening or between Screening and Day 0; recombinant or killed virus vaccines are permitted. Live seasonal flu and H1N1 vaccines are permitted =2 weeks prior to Screening.
12.Participation to another interventional research.
13.Inability to understand information concerning the protocol.
14.Pregnant or lactating women.
15.Patient under guardianship
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method